| Sanofi-Aventis (Suisse) SA - Vaxigrip, suspension injectable | | 70051 | | 02 | | Vaxigrip | | suspension injectable | | J07BB02 | | Influenza, gereinigtes Antigen | | 27.08.2025 | | |
| | Composition | | haemagglutininum influenzae A (H1N1) (Virus souche A/Victoria/4897/2022 (H1N1)pdm09-like: reassortant virus IVR-238 derived from A/Victoria/4897/2022) 15 µg, haemagglutininum influenzae A (H3N2) (Virus souche A/Croatia/10136RV/2023 (H3N2)-like: reassortant virus X-425A derived from A/Croatia/10136RV/2023) 15 µg, haemagglutininum influenzae B (Virus souche B/Austria/1359417/2021-like: B/Michigan/01/2021, wilde type (Victoria lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, ovalbuminum, neomycinum. | | Packungsbestandteile | | | | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 003 | | | | B | | Oui | | 004 | 10 | | | B | | Oui |
|
|
